Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease (View details on clinicaltrial.gov)
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study) (View details on clinicaltrial.gov)
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 plus Standard of Care versus Placebo plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE) (View details on clinicaltrial.gov)
A Phase Ib /Randomized Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells, or Standard-of-Care Allogeneic Graft (View details on clinicaltrial.gov)
A Phase Ib Study of oral decitabine/cedazuridine as maintenance therapy following allogeneic hematopoietic cell transplantation for patients with myeloid neoplasms (View details on clinicaltrial.gov)
A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis (View details on clinicaltrial.gov)
A randomized, double-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy (View details on clinicaltrial.gov)
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) (View details on clinicaltrial.gov)
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy (View details on clinicaltrial.gov)
Reduced intensity haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide and sirolimus/mycophenolate mofetil/RGI-2001 based GVHD prevention: a pilot study (View details on clinicaltrial.gov)